Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin Dosing in PCI (OPTIENOX-PCI)
NCT03145675Phase 4Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2017
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of enoxaparin in coronary artery disease (CAD) (4 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Anti-Xa level (CAG-90 min). Started May 2017; status: completed.
02
Drugs
enoxaparin
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT03145675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145675.